Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Matthew Goetz, MD, professor of oncology and pharmacology, Mayo Clinic, discusses a secondary analysis of the MONARCH 1 and MONARCH 2 clinical trials in breast cancer.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More